Drugmakers took big hits last year on failed clinical trials

02/6/2013 | Genetic Engineering & Biotechnology News

The suspension of a Phase IIb trial of Bristol-Myers Squibb's BMS-986094 nucleotide polymerase inhibitor resulted in a $1.8 billion write-off. Other expensive failures include a joint Pfizer-Johnson & Johnson candidate for Alzheimer's disease, an AstraZeneca and Targacept adjunct to antidepressant treatment, and an Eli Lilly & Co. schizophrenia drug.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care